EA201201464A1 - Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний - Google Patents

Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний

Info

Publication number
EA201201464A1
EA201201464A1 EA201201464A EA201201464A EA201201464A1 EA 201201464 A1 EA201201464 A1 EA 201201464A1 EA 201201464 A EA201201464 A EA 201201464A EA 201201464 A EA201201464 A EA 201201464A EA 201201464 A1 EA201201464 A1 EA 201201464A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
treatment
combined therapy
new combined
fibrous diseases
Prior art date
Application number
EA201201464A
Other languages
English (en)
Inventor
Флавио Золька
Ульрих Гюртлер
Ульрике Тонч-Грунт
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44275712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201464(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201201464A1 publication Critical patent/EA201201464A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к новым способам лечения онкологического и фиброзного заболевания, которые включают комбинированное введение ингибитора системы клеточных сигналов и/или ангиогенеза в сочетании с ингибитором киназы Aurora.
EA201201464A 2010-04-27 2011-04-21 Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний EA201201464A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10161229 2010-04-27
PCT/EP2011/056455 WO2011134898A1 (en) 2010-04-27 2011-04-21 New combination therapy in treatment of oncological and fibrotic diseases

Publications (1)

Publication Number Publication Date
EA201201464A1 true EA201201464A1 (ru) 2013-04-30

Family

ID=44275712

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201464A EA201201464A1 (ru) 2010-04-27 2011-04-21 Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний

Country Status (14)

Country Link
US (2) US20120107304A1 (ru)
EP (1) EP2563348A1 (ru)
JP (1) JP2013525398A (ru)
KR (1) KR20130069603A (ru)
CN (1) CN102869352A (ru)
AR (1) AR085173A1 (ru)
AU (1) AU2011246574A1 (ru)
BR (1) BR112012027197A2 (ru)
CA (1) CA2793616A1 (ru)
CL (1) CL2012002904A1 (ru)
EA (1) EA201201464A1 (ru)
MX (1) MX2012011576A (ru)
TW (1) TW201206441A (ru)
WO (1) WO2011134898A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009319A1 (en) 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
ES2858511T3 (es) 2012-10-17 2021-09-30 Exonate Ltd Compuestos útiles para tratar neovascularización ocular
ES2755983T3 (es) 2013-08-22 2020-04-24 Vanda Pharmaceuticals Inc Tratamiento del cáncer
WO2015029948A1 (ja) * 2013-08-26 2015-03-05 リンク・ジェノミクス株式会社 網膜色素上皮の障害を原因とする網膜疾患の予防または治療剤
CN107517590B (zh) * 2014-07-29 2021-11-12 威马克生物有限公司 与表皮生长因子受体-靶制剂有关的感受性预测用新型生物标志物及其用途
CN108367165B (zh) * 2015-10-07 2022-03-04 艾葳生物科技有限公司 治疗皮肤纤维化病症的组合物和方法
US20190388407A1 (en) * 2017-02-12 2019-12-26 Aiviva Biopharma, Inc. Multikinase inhibitors of vegf and tfg beta and uses thereof
CN110573161A (zh) * 2017-03-28 2019-12-13 勃林格殷格翰国际有限公司 用于治疗肌营养不良的方法的尼达尼布
CA3060247A1 (en) 2017-04-17 2018-10-25 Yale University Compounds, compositions and methods of treating or preventing acute lung injury
EP3752161A4 (en) * 2018-02-15 2021-12-22 Children's Hospital Medical Center FIBROSIS TREATMENT METHODS
AU2019340366A1 (en) * 2018-09-10 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
JP2022500384A (ja) * 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
US20230181582A1 (en) * 2020-05-22 2023-06-15 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with viral infections
CN114617969B (zh) * 2020-12-14 2023-08-25 上海市肿瘤研究所 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用
CN114213400B (zh) * 2022-01-10 2022-11-08 贵州大学 一种含噻吩的嘧啶类化合物其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75054C2 (ru) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Замещенные в положении 6 индолиноны, их получение и их применение как лекарственного средства
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
EP1473043A1 (en) * 2003-04-29 2004-11-03 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
JP4812763B2 (ja) 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ， インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
BRPI0519759A2 (pt) 2004-12-30 2009-03-10 Astex Therapeutics Ltd composiÇÕes farmacÊuticas
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
CA2629249C (en) 2005-11-11 2015-05-05 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors
EP1948179A1 (en) * 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
EP2016049A1 (en) 2006-04-24 2009-01-21 Boehringer Ingelheim International GmbH 3- (aminomethyliden) 2-indolinone derivatives and their use as cell proliferation inhibitors
AR060890A1 (es) 2006-05-15 2008-07-23 Boehringer Ingelheim Int Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2008077885A2 (en) 2006-12-22 2008-07-03 Boehringer Ingelheim International Gmbh 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer
CA2690567A1 (en) 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
WO2008152013A1 (en) * 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh Indolinone derivatives and their use in treating disease-states such as cancer
EP2231281A2 (en) * 2007-12-12 2010-09-29 AstraZeneca AB Combination comprising a mek inhibitor and an aurora kinase inhibitor
JP5651110B2 (ja) 2008-07-29 2015-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物

Also Published As

Publication number Publication date
CN102869352A (zh) 2013-01-09
AR085173A1 (es) 2013-09-18
EP2563348A1 (en) 2013-03-06
BR112012027197A2 (pt) 2016-07-19
US20120107304A1 (en) 2012-05-03
TW201206441A (en) 2012-02-16
JP2013525398A (ja) 2013-06-20
CL2012002904A1 (es) 2013-03-22
WO2011134898A1 (en) 2011-11-03
CA2793616A1 (en) 2011-11-03
MX2012011576A (es) 2012-11-23
KR20130069603A (ko) 2013-06-26
US20130289014A1 (en) 2013-10-31
AU2011246574A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA200970953A1 (ru) СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
EA201591145A1 (ru) Ингибиторы гистондеметилазы
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
EA201201400A1 (ru) Композиции и способы лечения аутоиммунных и других заболеваний
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EA201170155A1 (ru) Специфические антагонисты рецептора fgf-r4
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
UA111272C2 (uk) Конденсовані піримідинові похідні для інгібування тирозинкіназної активності
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
MX2017013142A (es) Terapia combinada para tratar cáncer.
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
EA201291194A1 (ru) Индолы
EA201491701A1 (ru) Лечение рака ингибиторами tor киназы
EA201491694A1 (ru) Лечение рака ингибиторами tor киназы
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft